-+ 0.00%
-+ 0.00%
-+ 0.00%

ALX Oncology Reports 92% Complete Response Rate with Evorpacept Combo in Frontline Indolent B-Cell Lymphoma Trial

Reuters·12/07/2025 13:00:12

Please log in to view news